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Introduction: The influence of different surgical approaches on breast cancer patients’ Health-related
Quality of life (HRQoL) is an important determinant when making decisions on the choice of treat-
ment. Knowledge on how patients actually perceive different surgical treatments regarding long-term
HRQoL is still scarce.
Materials & methods: 1065 patients with primary breast cancer operated on from 2008 to 2015 at
Helsinki University Hospital, Finland were prospectively followed-up for two years. They filled in two
HRQoL questionnaires, the EORTC QLQ C30 e BR 23 and the 15D, at baseline and at 3, 6, 12 and 24
months after surgery. Clinical data on treatments given and the course of recovery were collected from
patient records. Patients were divided into four mutually exclusive groups according to surgical method:
breast resection (n ¼ 415), oncoplastic resection (n ¼ 248), mastectomy (n ¼ 351) and immediate
reconstruction (n ¼ 51). Clinical data were combined with HRQoL scores and analysed as multivariate
modelling.
Results: All groups experienced initially worsening overall HRQoL after baseline. Oncoplastic resection
patients had the best body image and their HRQoL reached the highest level after treatments at 12
months whereas the reconstruction patients reached the highest HRQoL level first at 24 months. Mas-
tectomy patients had the lowest scores throughout the 24-month follow-up.
Conclusion: Extensive surgery, in terms of immediate reconstruction, led to slower HRQoL recovery than
oncoplastic techniques. Mastectomy patients are at risk of having the lowest HRQoL scores throughout
their recovery after surgery.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The method and timing of surgical treatment of breast cancer is
determined by the stage of the disease, general health of the patient
and patient’s and surgeon’s preferences. Breast cancer operations
differ in anatomical extent and treatment related morbidities [1,2].
Studies have indicated that the oncological safety is similar inde-
pendent of the surgical method [3e5]. Less is known about the
effect of the surgical method on Health-related quality of life
(HRQoL) which is considered an important aspect of high-quality
healthcare [6]. There are a number of different options forpital, Department of Plastic
US, Helsinki, Finland.
mervi.rautalin@helsinki.fi
r Ltd. This is an open access articleevaluating breast cancer patients perceived well-being, ranging
from historical self-assessment with questionnaires to modern
validated tools with specific and/or targeted questionnaires [7e9].
Studies on surgical methods reflecting HRQoL are still scarce, often
not prospective, and limited in their comparison of surgical
methods [3,6]. A recent systematic review addressed breast cancer
patients HRQOL and surgical methods based on studies in which
breast reconstruction was compared to mastectomy and breast-
conserving surgery. The systematic review included 16 eligible
studies in its meta-analysis the main findings of which were: breast
reconstruction and breast-conserving surgery both produce better
HRQOL outcomes in comparison to mastectomy. In addition, the
review concluded that it would be beneficial to incorporate both
breast/surgery specific and generic HRQOL instruments into breast
cancer studies to cover the heterogeneity of study groups [10].
Another recent, retrospective, study compared breast-conservingunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ment, the BREAST-Q. The study reported that breast-conserving
surgery was associated with less complications and need for revi-
sional surgery in comparison to both allogenous and autogenous
reconstruction methods. Furthermore, breast conserving surgery
led to better sexual well-being and satisfactionwith the breast [11].
Our study complements the above mentioned studies by investi-
gating breast cancer patients HRQOL in a prospective manner with
both breast cancer specific (EORTC QLQ-C30- BR23) and generic
(15D) HRQoL instruments. Furthermore, to find out whether
different surgical methods lead to different HRQOL results or
complications, our study includes all different surgical method
groups: breast-conserving surgery, mastectomy and breast recon-
structioning methods. HRQOL is an important aspect when
choosing surgical modalities for breast cancer patients.
Material and methods
Patients
1065 patients diagnosed with primary breast cancer at Helsinki
and Uusimaa Hospital District (HUS) Finland between September
2008 and September 2015 participated in the study. Participation
did not affect the treatment plan or offer financial compensation for
the patients. The study was approved by the University of Helsinki
Ethics committee (Permission 68 (June 11, 2008, 207/13/03/02/08)).
Part of the patients (n ¼ 130) received also peer support in the
context of a concomitant randomized substudy in addition to usual
care.
Questionnaires
Patients filled in an informed consent form and two quality of
life questionnaires: the generic 15D and the cancer specific EORTC
QLQ30-C30 with its QLQ-BR23 breast cancer specific module [8,9].
The questionnaires were collected at the time of diagnosis and later
at 3, 6, 12 and 24months after primary surgery. The generic and the
cancer-specific HRQoL instrument complement each other and
provide a wider perspective than a disease-specific instrument
alone. Both instruments are well established and have been used
widely to study breast cancer patients [12e16].
The 15D is a generic HRQoL instrument, which produces an
overall quality of life score and a health profile. The questionnaire
consists of 15 dimensions (Mobility, Vision, Hearing, Breathing,
Sleeping, Eating, Speech, Excretion, Usual Activities, Mental Func-
tion, Discomfort and Symptoms, Depression, Distress, Vitality,
Sexual Activity). Each dimension is rated by the patient from 1 (best
situation) to 5 (worst situation). In comparing the 15D scores, the
minimum clinically important difference (change) (MID) is 0.015
[17].
The EORTC QLQ-C30 is a cancer-specific HRQoL instrument
developed by the European Organisation for Research and Treat-
ment of Cancer. It is validated in more than 100 countries and in
wide use around the globe. The EORTC QLQ-C30 produces func-
tional status and symptom scores, which patients rate from 1 to 4
and 1 to 7 accordingly. It also provides an overall Quality of life
score. The BR23 is a set of 23 breast cancer specific questions which
produce 4 functional scores (Body Image, Sexual functioning, Sex-
ual enjoyment and Future perspective) and 4 symptom scores
(Systemic therapy side effects, Breast symptoms, Arm symptoms
and Upset by hair loss). Scores range from 0 to 100. For functional
scores a high score indicates good health whereas for symptom
scores a high score indicates problems in that area [9]. The signif-
icance of the changes in the EORTC score can be interpreted as
minimal for a score change between 5 and 10, intermediate for a1582change between 10 and 20, and large for a change >20 [18]. A MID
for the EORTC has not been firmly established and there is some
variation in the interpretation of the absolute values within
different studies [16,19].
Clinical data
Hospital records were viewed for medical data on patients’
health status, treatments given, and the course of surgical care.
Patients were divided into groups depending on the type of pri-
mary surgery: resection of the breast (n ¼ 415), oncoplastic
resection (n ¼ 248), mastectomy (n ¼ 351), and immediate
reconstruction (n ¼ 51).
Resection and oncoplastic resection were identified as being
either a simple resection of the breast cancer sitewith/without skin
and underlying fascia removed with moderate reshaping of breast
tissue if needed, or oncoplastic resection, which included removal
of the tumour and more excessive remodeling, reshaping and/or
replacing breast tissue with/without repositioning of the nipple in
order to achieve better cosmesis. Unlike the oncoplastic group, the
reconstruction group included also use of pedicled flaps. Thus the
classification we use for oncoplastic resection differs slightly from
some other classifications of oncoplastic methods (level 2 tech-
niques) [4,20]. The codes and techniques of the surgical methods
used were recorded from patient records. Based on the Nordic
Classification of Surgical Procedures (NCSP), oncoplastic resection
is defined by code HAB50 and thus differentiated from resection of
the breast HAB40 or lumpectomy HAB99.
The Reconstruction group consisted of patients who underwent
immediate breast reconstruction by either implants or autologous
tissue reconstruction (or both combined). Autologous tissue
reconstruction included both pedicled and microsurgical flaps.
Data on comorbidities were collected from hospital records
using the ICD-10 for identifying medical conditions. The Charlson
comorbidity index was used with the latest suggested rating for the
comorbidities (where certain comorbidities get higher and some
lower points compared to the initial introduction of the index)
[21e23]. In addition we recorded patients’ body-mass index (BMI),
smoking status and diabetes status if available, as those are
considered important influencers of HRQoL and factors that might
correlate with complications [24,25].
Complications were identified as a recorded abnormality in the
normal recovery process after surgery. They included wound
healing, bleeding and thromboembolic complications leading to
need of medication and/or extra procedures. Excessive seroma
formation needing aspiration more than 10 times was noted as a
potential independent factor influencing HRQoL even though
having seroma is considered to be part of the healing process and
not an actual complication.
Statistical analysis
The distribution of results for both HRQoL instruments was
slightly skewed. Therefore, non-parametric tests (Kruskal-Wallis)
were used in the analyses. For regression analysis we performed a
Box-Cox transformation to ensure normality of the data. Statistical
analysis was performed using SPSS 25.0 software and partly NCSS
software. We performed a stepwise linear regression analysis (One-
way ANOVA) to find possible explanatory factors affecting HRQoL.
Variables chosen for analysis were: tumour specifics (T-, N-, M-
classification, Grade of the disease), BMI, oncological treatments
(radiation therapy, chemotherapy and hormonal treatment),
whether or not having complications, excessive seroma formation
(seroma aspirated more than 10 times), multiple surgery and
recurrence of the disease.
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Patient characteristics
The age of the 1065 patients varied from 24 to 89 (Mean 59.7
years, SD 10.4) reconstruction patients being approximately 10
years younger than patients in the other groups. Part of our study
population (n ¼ 130) received peer support via telephone. In that
randomized intervention study therewas no statistically significant
difference in participants’ overall HRQoL compared to the controls
[26]. We also compared those patients overall HRQoL at all time-
points to that of the whole cohort but found no statistically sig-
nificant difference in the change of HRQoL.
Two breast cancer patients were male, 48 had had an earlier
breast cancer and 39 some other cancer at baseline. 107 patients
were active smokers.
The Charlson comorbidity points varied from 0 (no significant
comorbidities) to 1e7 (Mean 0.327, SD 0.733). Most of the recruited
patients (n ¼ 844) had no comorbidities. 119 patients had 1 point,
85 had 2 points and 14 had 3 points. Patients with Charlson index
4 (n ¼ 3) were excluded because of small group size. 72 patients
were diabetics.
Treatment
351 patients had mastectomy, 415 breast resection, 248 onco-
plastic resection and 51 immediate breast reconstruction (of which
76% were autologous). 402 patients had axillary clearance, the rest
sentinel node biopsy or no biopsy at all (DCIS with no immediate
reconstruction).
Radiation therapy was given to 840 patients (79% of all), 523
(49%) received chemotherapy, and 766 (72%) endocrine treatment.
119 (11%) patients received targeted therapy (anti HER2-
medication). Table 1 shows patient characteristics within the
treatment groups.
Follow up
105 (10%) patients had post-surgery wound infection and 32
(3%) some other complication. 18 (13%) of those having a compli-
cation were diabetic. 102 (10%) patients needed more than one
surgical operation at baseline and 26 (2%) additional surgery after
oncological treatments. This was due to positive margins or lateTable 1




Age mean (SD) 61.7 years (8.6) 59.4 years (8.6)
Axillary clearance n (%) 86 (21) 87 (35)
Oncological treatment
Radiation therapy n (%) 413 (100) 239 (96)
Chemotherapy n (%) 131 (32) 129 (52)
Endocrine treatment n (%) 279 (67) 187 (75)
Tumour characteristics
Ductal carcinoma n (%) 296 (71) 167 (67)
Lobular carcinoma n (%) 58 (14) 41 (17)
DCIS n (%) 18 (4) 7 (2.8)
T1/T2/T3/T4 n (%) 348(84)/60(15)/1(0)/0 170(69)/75(30)/
N0/N1/N2/N3 n (%) 317(76)/83(20)/12(3)/3(1) 150(61)/73(29)/
Grade 1/2/3 n (%) 170(41)/151(36)/92(22) 69(28)/105(42)/
15D/EORTC
Response %
3 Months 96.1/95.7 93.9/92.3
6 Months 96.9/95.4 95.1/92.7
12 Months 95.2/95.2 94.7/93.1
24 Months 90.6/89.6 88.6/86.5
1583axillary clearance after positive sentinel node biopsy. 309 (29%)
patients had post-surgery seroma. Of them 43 (4%) had to have the
seroma aspirated more than 10 times. 16 patients (1.5%) died, 32
(3%) patients had a recurrence and 22 (2%) another malignancy
during follow-up. 50 patients (14% of mastectomy group) under-
went delayed breast reconstruction during the two-year follow-up.
Response rate and missing data
During our study period of two years, patients whowerewilling
to participate and fill in the questionnaires, did so quite conscien-
tiously. Response rates are listed in Table 1. The number of missing
answers was similar in all groups at all timepoints thus not
affecting the analysis. Questions concerning sexual wellbeing were
most often left unanswered. Some data were missing at baseline
from around 5% of all respondents and the amount of missing data
increased a bit with time: at 12 months some data were missing
from 7.3% to 14.2% and at 24 months from 14.3 to 19.5% of re-
spondents, depending on the question.
HRQoL results
Age had a statistically significant effect on HRQoL measured
with the 15D (tested with Spearman correlation, p ¼ 0.008)
whereas it did not affect the EORTC results in a statistically signif-
icant manner (p ¼ 0.396).
Comorbidities affected HRQoL negatively when measured with
the 15D (p < 0.000) but not when measured with EORTC
(p ¼ 0.071). BMI correlated negatively with HRQoL with both in-
struments and at all measuring points (p < 0.05).
Active smoking (p ¼ 0.023) and higher BMI (p ¼ 0.006) corre-
lated statistically significantly with the occurrence of complica-
tions, whereas diabetes (p ¼ 0.561) did not.
Patients who had to go through more than 10 times of seroma
aspiration, experienced some negative effect on HRQoL at 6 months
measured with the 15D (p ¼ 0.040). Having to go through more
than one surgical procedure, irrespective of the reason, did not
seem to affect HRQoL with either measuring tool. Axillary clearance
correlated negatively with HRQoL based on both instruments from
3 months to 12 months (p < 0.01) but only EORTC showed negative
correlation on HRQoL in axillary clearance patients still at 24
months (p ¼ 0.002).




59.1 years (12.1) 48.5 years (11)
210 (60) 19 (37)
171 (49) 17 (33)
231 (66) 32 (63)
266 (76) 34 (67)
218 (62) 27 (53)
96 (27) 13 (26)
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(T-classification) affected only HRQoL measured with the EORTC at
12 months. Nodal status (N-classification) was significantly nega-
tively associated with HRQoL at all measuring points with the 15D
but with the EORTC only at 3 months. Distant metastasis (M-clas-
sification) influenced HRQoL measured with the EORTC at 24
months. Detecting a recurrence did not impair HRQoL. Of the
oncological treatments, radiation therapy or hormonal treatment
did not affect HRQoL, but chemotherapy led to deteriorated HRQoL
especially at 6 months. Table 2 represents regression analyses
results.
Appendix 1 shows the mean 15D scores at different timepoints
for different groups. In all groups the mean score deteriorated in a
clinically important manner from baseline to 3 months. Of the
treatment groups, the oncoplastic resection group showed clini-
cally important improvement from the initially worst situation (at 3
months) at 12 and 24 months, and the reconstruction group at 24
months. In the resection and mastectomy groups the 15D score did
not improve in a clinically significant manner from the 3-month
lowest level during the entire 24-month follow-up.
Based on both instruments, the mastectomy group had the
lowest HRQoL score at baseline and at 24 months compared to the
other groups. According to the EORTC, the reconstruction group
had the most marked improvement of HRQoL at 24 months. Fig. 1
and Fig. 2 show mean HRQoL scores within groups by time.
The EORTC symptom scales showed constantly that fatigue, pain
and sleeping were impaired in all groups at all measuring points.
The mastectomy group reported pain more than the other
groups throughout the study, but the differences were statistically
significant only at baseline.
To study the difference of EORTC patient-reported symptoms
between our study groups we did a variance analysis for all the
studied time points with all reported symptom scales. Tables 3 and
4 demonstrate those EORTC results that were different between
study groups at timepoints baseline and 24 months.
Based on EORTC Functional scales, reconstruction patients had
the best Physical and Sexual functioning throughout the study
compared to the other groups. Their social functioning scale was
the best at baseline and at 24 months, but their Body image score
was theworst of all groups at 24months.When comparing changes
in mean EORTC scores at 24 months, there were statistically sig-
nificant differences between groups in Financial difficulties, Phys-
ical functioning, Body image, Sexual functioning and Arm
symptoms. Body image also decreased in a clinically significant
manner (intermediate 10-20-point change) from baseline to 24
months in the mastectomy and reconstruction groups. In arm
symptoms, the oncoplastic and mastectomy groups reported aTable 2
Regression analysis results. Statistical significance (p-values) and standard coefficients of
below in box.
Variable 3 Months 6 Months
p-value Std Co p-value
Grade EORTC 0.015* -0.094 ns
15D 0.000*** -0.150 ns
T - class EORTC ns ns
15D ns ns
N - class EORTC 0.000*** -0.174 ns
15D 0.001*** -0.131 0.032*
M - class EORTC ns ns
15D ns ns
BMI EORTC 0.012* -0.094 -
15D 0.002** -0.113
Chemotherapy EORTC - 0.000***
15D 0.000***
*p < 0.05, **p < 0.01, ***p < 0.001.
1584minimally clinically important decrease (5e10 points) in EORTC
points [18]. At 12 months, patients who had delayed reconstruction
did not differ from the rest of the mastectomy patients. At 24
months, there was only a small and insignificant difference in the
EORTC global score (74.32 in the mastectomy group compared to
73.84 with delayed reconstruction). However, regarding the 15D,
the delayed reconstruction patients reported a borderline clinically
importantly better total 15D score at 24 months compared to the
rest of the mastectomy patients (0.915 vs 0.890).
Discussion
Our prospective study describes the healing process of breast
cancer patients in Finland’s biggest breast cancer and plastic sur-
gery units. We used well established and accepted HRQoL ques-
tionnaires available at the time of onset of this study. Unfortunately,
data on baseline response rate is missing as the recruitment process
was long and interrupted at some time points to allow collection of
data for some other breast cancer projects of the hospital. As a
consequence of that, we are not absolutely certain about the
baseline response rate and do not report it here. However, once the
patients had agreed to participate, they responded to the follow-up
questionnaires very well as evidence by the high response rates
over 90%.
The amount of missing data was similar in all groups. Questions
about sexual wellbeing seemed to be the most difficult to answer
for all patients. Searching for common factors for non-response did
not reveal any obvious reasons; some patients did not answer at
some timepoints but then answered at the next one whereas some
patients suffering from recurrence returned all questionnaires at all
timepoints. Neither the mean age nor the number of complications
differed between respondents and non-respondents. The only dif-
ference we found was in the mastectomy group in which the group
of non-respondents comprised a larger percentage of patients
having received chemotherapy (76% vs. 66%). However, we have no
reason to assume that some groups would be over- or underrep-
resented in our study.
High research activity and multiple ongoing studies in our clinic
affected the quite long recruitment period of our study: at times we
were forced to halt our recruitment process so that the burden
caused by studies for the same patients didn’t get too high.
At the onset of our study, in year 2008, the proportion of
oncoplastic techniques of all breast conserving techniques was
13.8%. That proportion had risen to 44.3% in year 2011, and there-
after varied yearly from 31.9% to 48.3%. All study patients received
similar oncological treatment regardless of when they were
recruited to the study. In Finland, reconstruction methods havenominated factors’ effect on overall HRQoL at measuring points: EORTC above, 15D
12 Months 24 Months










-0.245 0.032* -0,075 0.013* -0.082
-0.158 ns ns
Fig. 1. Mean EORTC HRQoL scores for the study groups by time.
Fig. 2. Mean 15D HRQoL scores for the study groups by time.
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has not changed radically over time. This may be a cultural differ-
ence as our clinic has a strong tradition of microsurgical recon-
struction - or a result of our easily accessible and virtually free
health care for the patient. Patients pay for their hospital stay, but
the extent of the surgical procedure is not a financial issue for the
patiente the amount of personal cost being the samewhether they
have a resection procedure or a microsurgical operation.
Both EORTC and 15D describe the healing process of breast
cancer patients well. The ceiling effect (patients reporting prefect
health) was relatively low at baseline for both instruments: 8% for
15D and 15.3% for EORTC. At later measurement points the ceiling
effect was even lower. Mastectomy patients had the lowest re-
ported HRQoL at baseline and at 24 months, which might be
because of a heavier disease burden. According to generally
approved guidelines regarding which patients can be offered im-
mediate reconstruction, the reconstruction group is probably
healthier in many aspects. Still, all breast cancer patients deserve
careful planning on what would be the best surgical approach for
each individual [25].1585Methods of breast reconstruction cannot be randomized
because surgical treatment is always tailored for each patient.
Following the AMAROS-study, the international guidelines for
breast cancer treatment have changed and nowadays axillary
clearance is performed less frequently [27,28]. Our results are in
line with those of past studies: pain, fatigue and sleeping disorders
are important factors that need to be addressed throughout the
breast cancer patients’ care. Large studies, such as ours, are needed
to investigate HRQoL in the pursuit to provide best possible treat-
ment for each individual.
Conclusions
Our study showed that reconstruction patients had good phys-
ical functioning and their sexual wellbeing was the least impaired
of all study groups. Patients treated with oncoplastic resection had
the best body image and their overall HRQoL reached a higher level
already at 12 months after surgery whereas reconstruction patients
needed a longer time to recover. Mastectomy patients had the
lowest scores which needs to be taken into account when planning
Table 3
EORTC: Symptom, Functional and Breast cancer specific scores that differed statistically significantly between study groups at Baseline.B Bonferroni’s test can’t identify which
groups differ, *p < 0.05, **p < 0.01, ***p < 0.001. Mean score, Standard Deviation and 95% Confidence Interval. Highest mean underlined.
Baseline Resection Oncoplastic Resection Mastectomy Reconstruction
p Mean SD 95% CI Mean SD 95% CI Mean SD 95% CI Mean SD 95% CI

















































































Means, Standard deviation and 95% Confidence intervals between groups regarding those EORTC Functional and Symptom scores that were statistically significantly different
between groups at 24 Months.B Bonferroni’s test can’t identify which groups differ, *p < 0.05, **p < 0.01, ***p < 0.001. Highest mean underlined.
24 Months Resection Oncoplastic Resection Mastectomy Reconstruction
p Mean SD 95% CI Mean SD 95% CI Mean SD 95% CI Mean SD 95% CI
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associated with less mastectomies and probably higher HRQoL.
Reconstructive surgery appears to, according to our results, provide
good quality of life. In practice, for the planning of surgical options,
these results could be useful: patients should be offered oncoplastic
surgical treatment when applicable. Those, who require mastec-
tomy, should be offered reconstructive options and they should be
warned about the possibility that regaining good HRQoLmay take a
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6 Months 0.896 0.896 0.886 0.888
12 Months 0.898 0.906** 0.891 0.887
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[1] Mansell J, Weiler-Mithoff E, Martin J, Khan A, Stallard S, Doughty JC, et al. How
to compare the oncological safety of oncoplastic breast conservation surgery -
to wide local excision or mastectomy? Breast 2015;24:497e501.
[2] Ojala K, Meretoja TJ, Leidenius MHK. Aesthetic and functional outcome after
breast-conserving surgery - comparison between conventional and onco-
plastic resection. EJSO 2017;43:658e64.
[3] Pukancsik D, Kelemen P, Ujhelyi M, Kovacs E, Udvarhelyi N, Meszaros N, et al.
Objective decision making between conventional and oncoplastic breast-
conserving surgery or mastectomy: an aesthetic and functional prospective
cohort study. EJSO 2017;43:303e10.
[4] Pearce BCS, Fiddes RN, Paramanathan N, Chand N, Laws SAM, Rainsbury RM.
Extreme oncoplastic conservation is a safe new alternative to mastectomy.
EJSO 2019 Sep 5. https://doi.org/10.1016/j.ejso.2019.09.004. pii: S0748-
7983(19)30664-X, [Epub ahead of print].
[5] Ej Campbell, L Romics. Oncological safety and cosmetic outcomes in onco-
plastic breast conservation surgery, a review of the best level of evidence
literature. Breast Cancer 2017;9:521e30. Published online 2017 Aug 4, 10.
2147/BCTT.S113742 PMCID: PMC5552002 PMID: 28831273.
[6] Howes BHL, Watson DI, Xu C, Fosh B, Canepa M, Dean NR. Quality of life
following total mastectomy with and without reconstruction versus breast-
conserving surgery for breast cancer: a case-controlled cohort study. J Plast
Reconstr Aesthetic Surg 2016;69:1184e91.
[7] Jahkola T. Self-perceptions of women after early breast cancer surgery. EJSO
1998;24:9e14.
[8] Sintonen H. The 15D instrument of health-related quality of life: properties
and applications. Ann Med 2001;33(5):328e36. https://doi.org/10.3109/
07853890109002086.
[9] The EORTC Quality of Life Group & EORTC Quality of Life Unit. Guidelines for
assessing quality of life in EORTC Clinical Trials. Brussels: EORTC Data Center;
2002, ISBN 2-930064-27-7.
[10] Zehra S, Doyle F, Barry M, Walsh S, Kell MR. Health-related quality of life
following breast reconstruction compared to total mastectomy and breast-
conserving surgery among breast cancer survivors: a systematic review and
meta-analysis. Breast Cancer 2020 Jul;27(4):534e66. https://doi.org/10.1007/
s12282-020-01076-1. Epub 2020 Mar 12. PMID: 32162181.
[11] Stein MJ, Karir A, Arnaout A, Roberts A, Cordeiro E, Zhang T, et al. Quality-of-
Life and surgical outcomes for breast cancer patients treated with therapeutic
reduction mammoplasty versus mastectomy with immediate reconstruction.
Ann Surg Oncol 2020;27:4502e12. https://doi.org/10.1245/s10434-020-
08574-8.1587[12] Rautalin M, F€arkkil€a N, Sintonen H, Saarto T, Taari K, Jahkola T, et al. Health-
related quality of life in different states of breast cancer - comparing different
instruments. Acta Oncol 2018 May;57(5):622e8. https://doi.org/10.1080/
0284186X.2017.1400683. Epub 2017 Nov 15. PMID: 29140139.
[13] Klein D, Mercier M, Abeilard E, Puyraveau M, Danzon A, Dalstein V, et al. Long-
term quality of life after breast cancer: a French registry-based controlled
study. Breast Canc Res Treat 2011 Aug;129(1):125e34. https://doi.org/
10.1007/s10549-011-1408-3. Epub 2011 Feb 22. PMID: 21340477.
[14] F€arkkil€a N, Torvinen S, Roine RP, Sintonen H, H€anninen J, Taari K, et al. Health-
related quality of life among breast, prostate, and colorectal cancer patients
with end-stage disease. Qual Life Res 2014 May;23(4):1387e94. https://
doi.org/10.1007/s11136-013-0562-y. Epub 2013 Nov 1. PMID: 24178630.
[15] Dauplat J, Kwiatkowski F, Rouanet P, Delay E, Clough K, Verhaeghe JL, et al.
C. Pomel and the STIC-RMI working group: quality of life after mastectomy
with or without immediate breast reconstruction. BJS 2017;104:1197e206.
[16] Kindts I, Laenen A, van deer Akken M, Weltens C. PROMs following breast-
conserving therapy for breast cancer: results from a propective longitudinal
monocentric study. Support Care Canc 2019;27:4123e32.
[17] Alanne S, Roine RP, Rasanen P, et al. Estimating the minimum important
change in the 15D scores. Qual Life Res 2015;24:599e606.
[18] Osaba D, Rodrigues G, Pymes J, et al. Interpreting the significance of changes
in health-related quality of life-scores. J Clin Oncol 1998;16:139e44.
[19] Cocks K, King MT, Velikova G, de Gastro Jr G, Martyn St-James M, Fayers PM,
et al. Evidence-based guidelines for interpreting change scores for European
organisation for the research and treatment of cancer quality of life ques-
tionnaire core 30. Eur J Canc 2012;48:1713e21.
[20] Clough KB, Kaufman GJ, Nos C, Buccimazza I, Im Sarfati. Improving breast
cancer surgery: a classification and quadrant per quadrant atlas for onco-
plastic surgery. Ann Surg Oncol 2010;17:1375e91.
[21] Charlson ME, Pompei P, Ales KL, MaCKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chron Dis 1987;40(5):373e83.
[22] Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding
algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative
data. Med Care 2005;43:1130e9. 11.
[23] Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and
validating the Charlson comorbidity index and score for risk adjustment in
hospital discharge abstracts using data from 6 countries. Am J Epidemiol
2011;173:676e82. https://doi.org/10.1093/aje/kwq433. Epub 2011 Feb 17, 6.
[24] Theocharidis V, Katsaros I, Sgouromallis E, Serifis N, Boikou V, Tasigiorgos S,
et al. Current evidence on the role of smoking in plastic surgery elective
procedures: a systematic review and meta-analysis. J Plast Reconstr Aesthetic
Surg 2018;71:624e36.
[25] Boczar D, Huayllani MT, Forte AJ, Rinker B. Microsurgical breast reconstruction
in the obese patient using abdominal flaps. Ann Plast Surg 2020. https://
doi.org/10.1097/SAP.0000000000002284. 00:00-00.
[26] A. Toija, T. Kettunen, M. Leidenius, T. Vainiola, R.P. Roine. Effectiveness of peer
support on health-related quality of life in recently diagnosed breast cancer
patients: a randomized controlled trial. Support Care Canc https://doi.org/10.
1007/s00520-018-4499-0.
[27] Donker M, van Tienhoven G, Straver ME, Meijnen P, vn de Velde CJH,
Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel
node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multi-
centre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15:
1303e10. 12.
[28] Moossdorff M, Nakhlis F, Hu J, Barry WT, Losk K, Haskett C, et al. The potential
impact of AMAROS on the management of the axilla in patients with clinical
T1-N0 breast cancer undergoing primary total mastectomy. Ann Surg Oncol
2018;25:2612e9.
